Search Results

Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin’s lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. 1 – 3 However, those with relapsed and/or refractory (R

experience relapses. Clinicians are tasked with selecting the best treatment options for these progressions from among a growing cascade of regimens. Explaining this treatment landscape at the NCCN 2023 Annual Conference was Natalie S. Callander, MD

approaching those achieved in patients who are HIV-negative. 6 - 10 Recent studies suggest a similar trend in HIV-cHL. 11 , 12 However, a paucity of prospective data exists for the treatment of relapsed disease, although modest success has been reported with

“There are a number of salvage chemotherapy regimens in relapsed or refractory [R/R] Hodgkin lymphoma [HL],” revealed Leo I. Gordon, MD, Abby and John Friend Professor of Cancer Research and Professor of Medicine, Division of Hematology

Treatment for Hodgkin lymphoma (HL) has improved so that most patients, even those with high-risk disease, are now cured with primary therapy. 1 , 2 However, for patients with primary refractory disease, or those experiencing relapse after

As new drugs continue to be approved for the treatment of multiple myeloma (MM) at a rapid pace, there have never been more treatment choices available for patients with relapsed disease. Except for those with the highest-risk disease or plasma

thalidomide analogs in human multiple myeloma cells: therapeutic implications . Blood 2002 ; 99 : 4525 – 4530 . 16. Jagannath S Barlogie B Berenson J . A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma . Br J Haematol

In recent years, the treatment landscape for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has seen significant advancements, ushering in an era of targeted therapies that have transformed patient outcomes

“Immunotherapy has changed the treatment paradigm for myeloma,” having significantly improved overall survival (OS) in patients with newly diagnosed and relapsed/refractory (R/R) disease, said Shaji K. Kumar, MD, Professor of Medicine, Research

lymphomas (MZLs). Although the diseases share similarities, FL and MZL have distinct biological differences that affect presentation and treatment. Dr. LaCasce summarized the data from clinical trials on the use of targeted therapies for relapsed or